Detailed view for Rv0097

Basic information

TDR Targets ID: 7163
Mycobacterium tuberculosis, Possible oxidoreductase

Source Database / ID:  Tuberculist 

pI: 6.5644 | Length (AA): 289 | MW (Da): 32641 | Paralog Number: 1

Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0

Druggability Group : DG2

Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable

Pfam domains

PF02668   Taurine catabolism dioxygenase TauD, TfdA family

Gene Ontology

Mouse over links to read term descriptions.
GO:0016491   oxidoreductase activity  
GO:0009055   electron carrier activity  
GO:0055114   oxidation reduction  

Metabolic Pathways

This gene is not mapped to any metabolic pathway in KEGG.

Structural information

Modbase 3D models:

There are 2 models calculated for this protein. More info on these models, including the models themselves is available at: Modbase

Target Beg Target End Template Template Beg Template End Identity Evalue Model Score MPQS zDope
1 280 6dch (A) 31 315 45.00 0 1 1.62616 -1.44
1 280 1otj (A) 5 275 26.00 0 1 1.36016 -0.98

Help me make sense of these data.

Target Beg: first modeled residue
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)

A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.

PDB Structures:

No structure availble in the PDB for this protein


Upregulation Percent Ranking Stage Dataset
Mid 40-60% percentile Dormant phase, Dormant phase. hasan murphy
Show/Hide expression data references
  • hasan Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis.
  • murphy Identification of gene targets against dormant phase Mycobacterium tuberculosis infections.


Ortholog group members (OG5_129515)

Species Accession Gene Product
Candida albicans CaO19.1167   one of 5 potential alpha-ketoglutarate-dependent taurine dioxygenase genes (catabolic utilization of sulphate) similar to S. cer
Candida albicans CaO19.8760   one of 5 potential alpha-ketoglutarate-dependent taurine dioxygenase genes (catabolic utilization of sulphate) similar to S. cer
Candida albicans CaO19.6398   one of 5 potential alpha-ketoglutarate-dependent taurine dioxygenase genes (catabolic utilization of sulphate) similar to S. cer
Candida albicans CaO19.9207   one of 5 potential alpha-ketoglutarate-dependent taurine dioxygenase genes (catabolic utilization of sulphate) similar to S. cer
Candida albicans CaO19.13756   one of 5 potential alpha-ketoglutarate-dependent taurine dioxygenase genes (catabolic utilization of sulphate) similar to S. cer
Escherichia coli b0368   taurine dioxygenase, 2-oxoglutarate-dependent
Mycobacterium leprae ML1992   POSSIBLE OXIDOREDUCTASE
Mycobacterium tuberculosis Rv3406   Probable dioxygenase
Mycobacterium tuberculosis Rv0097   Possible oxidoreductase
Mycobacterium ulcerans MUL_0904   taurine catabolism dioxygenase, TauD
Mycobacterium ulcerans MUL_4854   oxidoreductase
Saccharomyces cerevisiae YLL057C   Jlp1p


Rv0097 has direct evidence of essentiality
Gene/Ortholog Organism Phenotype Source Study
mtu98 this record Mycobacterium tuberculosis non-essential nmpdr
mtu3467 Mycobacterium tuberculosis non-essential nmpdr
b0368 Escherichia coli non-essential goodall
Show/Hide essentiality data references
  • neb C. elegans RNAi phenotypes Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs
  • sidik A Genome-wide CRISPR Screen in Toxoplasma Identifies Essential Apicomplexan Genes. Sidik, Saima M., et al. "A genome-wide CRISPR screen in toxoplasma identifies essential apicomplexan genes." Cell 166.6 (2016): 1423-1435.
  • gerdes Experimental determination and system-level analysis of essential genes in E. coli MG1655 Gerdes et al., J Bacteriol. 2003 185:5673-84
  • wormbase C. elegans RNAi experiments WormBase web site,, release WS170
  • shigen Profiling of E. coli Chromosome (PEC) National Institute of Genetics, Japan
  • alsford High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome Genome Res 2011, 21:915-924
  • blattner Systematic mutagenesis of the E. coli (MG1655) genome J Bacteriol 2004, 186:4921-4930
  • keio Systematic single-gene knock-out mutants of E. coli K12 The Keio Collection
  • plasmo Functional Profiling of a Plasmodium Genome Reveals an Abundance of Essential Genes. Bushell, Ellen, et al. "Functional profiling of a Plasmodium genome reveals an abundance of essential genes." Cell 170.2 (2017): 260-272.
  • goodall The Essential Genome of Escherichia coli K-12 (Transposon directed high-throughput mutagenesis) Goodall, Emily CA, et al. "The essential genome of Escherichia coli K-12." mBio 9.1 (2018): e02096-17.
  • nmpdr Genome-scale essentiality datasets from published studies (M. tuberculosis) National Microbial Pathogen Data Resource
  • yeastgenome Systematic deletion of yeast genes Saccharomyces Genome Database

Phenotypes and Validation (curated)

We have no manually annotated phenotypes for this target. What does this mean? / Care to help?

In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.

In any case, if you have information about papers containing relevant validation data for this target, please contact us.

Annotated validation

No validation data for this target

Associated compounds / Druggability

Known modulators for this target

No chemical compounds associated to this gene

Predicted associations

By orthology with druggable targets
Non orthologous druggable targets
By sequence similarity to non orthologous druggable targets
No additional associated druggable targets

Obtained from network model

Ranking Plot

Putative Drugs List

Compound Raw Global Species
0.0287 0.3476 1
0.0098 0.9508 0.5
0.0087 0.9507 0.5
0.0101909 0.730886 0.5
0.0069 0.5911 1


Assay information

No assay information for this target.

Reagent availability

No reagent availability information for this target.

Bibliographic References

No literature references available for this target.

If you have references for this gene, please enter them in a user comment (below) or Contact us.

User comments

No user comments are available for this gene. Log in to add comments, or register.

Enter your comment

User ()
Gene identifier Rv0097 (Mycobacterium tuberculosis), Possible oxidoreductase
Title for this comment